RSS-Feed abonnieren

DOI: 10.1055/s-0042-1760375
Costimulatory Molecules OX40 and OX40L Upregulation in Oral Squamous Cell Carcinoma: A Blood-Based Study

Abstract
Objectives This research aimed to determine OX40 and OX40L mRNA expression in blood samples of naive oral squamous cell carcinoma (OSCC) patients in different histological grades and clinical stages. The in silico analysis was performed using the STRING database for functional association and a better understanding of the interactions of OX40 and its ligand with other proteins.
Materials and Methods In this study, we recruited 141 newly diagnosed patients of OSCC. Levels of OX40 and OX40L mRNA expression were explored using real-time quantitative polymerase chain reaction. An in silico tool was also utilized to evaluate the OX40/OX40L interactome.
Results The results showed higher OX40 expressional levels in the late stage (23-fold) compared with the early stage (8.5-fold) (p = < 0.001). A similar trend was seen in OX40L mRNA expression, revealing a fold change of 5.8 in the early stage in comparison to 9.9-fold change in the late stage (p = < 0.001). Overexpression of OX40 and OX40L was found in different histological grades (p = 0.005 and p = < 0.001, respectively). Overexpression of OX40 and OX40L was detected in habits such as smoking and paan intake, whereas statistically significant upregulation was observed in the cheek, lip, and alveolus tumors. However, there was no substantial difference in OX40 and OX40L expression based on age or gender. The functional interactions, that is, interactomes of OX40 and OX40L with other proteins have been determined by in silico analysis.
Conclusion Based on current study findings, despite OX40 and OX40L upregulation in newly diagnosed OSCC patients, it is speculated that the physiological function of these molecules is altered due to immune system exhaustion.
Publikationsverlauf
Artikel online veröffentlicht:
18. Januar 2023
© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Sung H, Ferlay J, Siegel RL. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71 (03) 209-249
- 2 Conway DI, Purkayastha M, Chestnutt IG. The changing epidemiology of oral cancer: definitions, trends, and risk factors. Br Dent J 2018; 225 (09) 867-873
- 3 Siddiqi K, Shah S, Abbas SM. et al. Global burden of disease due to smokeless tobacco consumption in adults: analysis of data from 113 countries. BMC Med 2015; 13 (01) 194
- 4 Sahaf R, Naseem N, Rehman Aur, Anjum R, Nagi AH. A study of 89 cases of oral squamous cell carcinoma presenting at Teaching Hospitals of Lahore, Pakistan. J Pak Dent Assoc 2017; 26 (01) 26-31
- 5 Markopoulos AK. Current aspects on oral squamous cell carcinoma. Open Dent J 2012; 6 (01) 126-130
- 6 Tsantoulis PK, Kastrinakis NG, Tourvas AD, Laskaris G, Gorgoulis VG. Advances in the biology of oral cancer. Oral Oncol 2007; 43 (06) 523-534
- 7 Bagan JV, Scully C. Recent advances in Oral Oncology 2007: epidemiology, aetiopathogenesis, diagnosis and prognostication. Oral Oncol 2008; 44 (02) 103-108
- 8 Lingen MW, Kalmar JR, Karrison T, Speight PM. Critical evaluation of diagnostic aids for the detection of oral cancer. Oral Oncol 2008; 44 (01) 10-22
- 9 Soman C, Alghamdi SRM, Alazemi FNM, Alghamdi AAA. Cyberknife radiosurgery for the treatment of head and neck cancer: a systematic review. Eur J Dent 2022; 16 (02) 266-273
- 10 Selvido DI, Bhattarai BP, Riddhabhaya A, Vongsawan K, Arunpraphan S, Wongsirichat N. A review on the application of silver nanoparticles in oral and maxillofacial surgery. Eur J Dent 2021; 15 (04) 782-787
- 11 Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144 (05) 646-674
- 12 Marin-Acevedo JA, Dholaria B, Soyano AE, Knutson KL, Chumsri S, Lou Y. Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol 2018; 11 (01) 39
- 13 Deng J, Zhao S, Zhang X. et al. OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer. Onco Targets Ther 2019; 12: 7347-7353
- 14 Szklarczyk D, Gable AL, Nastou KC. et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res 2021; 49 (D1): D605-D612
- 15 Xie F, Wang Q, Chen Y. et al. Costimulatory molecule OX40/OX40L expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study. Pathol Res Pract 2010; 206 (11) 735-739
- 16 Montler R, Bell RB, Thalhofer C. et al. OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer. Clin Transl Immunology 2016; 5 (04) e70
- 17 Lecerf C, Kamal M, Vacher S. et al. Immune gene expression in head and neck squamous cell carcinoma patients. Eur J Cancer 2019; 121: 210-223
- 18 Kashima J, Okuma Y, Hosomi Y, Hishima T. High serum OX40 and OX40 ligand (OX40L) levels correlate with reduced survival in patients with advanced lung adenocarcinoma. Oncology 2020; 98 (05) 303-310
- 19 Ruby CE, Weinberg AD. The effect of aging on OX40 agonist-mediated cancer immunotherapy. Cancer Immunol Immunother 2009; 58 (12) 1941-1947
- 20 Yi JS, Cox MA, Zajac AJ. T-cell exhaustion: characteristics, causes and conversion. Immunology 2010; 129 (04) 474-481
- 21 Aggarwal S, Sharma SC, N. Das S. Dynamics of regulatory T cells (Tregs) in patients with oral squamous cell carcinoma. J Surg Oncol 2017; 116 (08) 1103-1113
- 22 Liu S, Liu D, Li J, Zhang D, Chen Q. Regulatory T cells in oral squamous cell carcinoma. J Oral Pathol Med 2016; 45 (09) 635-639
- 23 Weixler B, Cremonesi E, Sorge R. et al. OX40 expression enhances the prognostic significance of CD8 positive lymphocyte infiltration in colorectal cancer. Oncotarget 2015; 6 (35) 37588-37599
- 24 Xie K, Xu L, Wu H. et al. OX40 expression in hepatocellular carcinoma is associated with a distinct immune microenvironment, specific mutation signature, and poor prognosis. Oncoimmunology 2018; 7 (04) e1404214
- 25 Haak F, Obrecht I, Tosti N. et al. Tumor infiltration by OX40+ cells enhances the prognostic significance of CD16+ cell infiltration in colorectal cancer. Cancer Contr 2020; 27 (01) 1073274820903383
- 26 Sani AI, Rubab Z, Usman S, Ahmed SZ, Hosein M, Shahid MA. Serum levels of OX40 in early and late-stage oral squamous cell carcinoma. Cureus 2021; 13 (04) e14597
- 27 Sani AI, Rubab Z, Usman S, Ahmed SZ, Hosein M. Role of OX40 and its ligand as costimulatory modulators in cancer immunotherapy. AIMS Mol Sci 2021; 8 (03) 161-173
- 28 Prasetyaningtyas N, Jatiatmaja NA, Radithia D. et al. The response of the tongue epithelial on cigarette smoke exposure as a risk factor for oral cancer development. Eur J Dent 2021; 15 (02) 320-324
- 29 Shafique K, Mirza SS, Vart P. et al. Areca nut chewing and systemic inflammation: evidence of a common pathway for systemic diseases. J Inflamm (Lond) 2012; 9 (01) 22
- 30 Shi JZ, Wang LY, Zhu Y. et al. OX40 ligand levels and high-sensitivity C-reactive protein levels in blood from local coronary plaque and the femoral artery in patients with acute coronary syndrome or stable angina. J Int Med Res 2011; 39 (04) 1275-1283
- 31 Wang YX, An N, Ouyang XY. [Molecular mechanism involved in adhesion of monocytes to endothelial cells induced by nicotine and Porphyromonas gingivalis-LPS]. Beijing Da Xue Xue Bao 2015; 47 (05) 809-813